Non-Rapid Eye Movement Sleep Parasomnias and Migraine: A Role of Orexinergic Projections

Antonietta Messina1†, Ilaria Bitetti2†, Francesco Precenzano2, Diego Iacono3,4,5, Giovanni Messina4**, Michele Roccella1, Lucia Parisi1, Margherita Salerno1, Anna Valenzano6, Agata Maltese6, Monica Salerno6, Francesco Sessa6, Giuseppe Davide Albano6, Rosa Marotta6, Ines Villano1, Gabriella Marsala9, Christian Zammit10, Francesco Lavano6, Marcellino Monda6, Giuseppe Cibelli6, Serena Marianna Lavano8, Beatrice Galai11, Roberto Toraldo2, Vincenzo Monda1 and Marco Carotenuto2

1 Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy, 2 Clinic of Child and Adolescent Neuropsychiatry, Center for Childhood Headache, Department of Mental Health, Physical and Preventive Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy, 3 Neurodevelopmental Research Lab, Biomedical Research Institute of New Jersey (BRInj), Cedar Knolls NJ, United States, 4 Neuroscience Research, MidAtlantic Neonatology Associates, Atlantic Health System, Morristown NJ, United States, 5 Neurpathology Research, MidAtlantic Neonatology Associates (MANA) and Biomedical Research Institute of New Jersey (BRInj), Morristown, NJ, United States, 6 Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, 7 Child Neuropsychiatry, Department of Psychology and Pedagogical Sciences, University of Palermo, Palermo, Italy, 8 Department of Health Sciences, University “Magna Graecia”, Catanzaro, Italy, 9 Struttura Complessa di Farmacia, Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Foggia, Foggia, Italy, 10 Anatomy Department, Faculty of Medicine and Surgery, University of Malta, Msida, Malta, 11 Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy

Introduction: Sleep and migraine share a common pathophysiological substrate, although the underlying mechanisms are unknown. The serotonergic and orexinergic systems are both involved in the regulation of sleep/wake cycle, and numerous studies show that both are involved in the migraine etiopathogenesis. These two systems are anatomically and functionally interconnected. Our hypothesis is that in migraine a dysfunction of orexinergic projections on the median raphe (MR) nuclei, interfering with serotonergic regulation, may cause Non-Rapid Eye Movement parasomnias, such as somnambulism.

Hypothesis/theory: Acting on the serotonergic neurons of the raphe nuclei, the dysfunction of orexinergic neurons would lead to a higher release of serotonin. The activation of serotonergic receptors located on the walls of large cerebral vessels would lead to abnormal vasodilatation and consequently increase transmural pressure. This process could activate the trigeminal nerve terminals that innervate vascular walls. As a consequence, there is activation of sensory nerve endings at the level of hard vessels in the meninges, with release of pro-inflammatory peptides (e.g., substance P and CGRP). Within this hypothetical frame, the released serotonin could also interact with trigeminovascular afferents to activate and/or facilitate the release of the neuropeptide at the level of the trigeminal ganglion. The dysregulation of the physiological negative feedback of serotonin on the orexinergic neurons, in turn, would contribute to an alteration of the whole system, altering the sleep–wake cycle.
INTRODUCTION/BACKGROUND OF MIGRAINE AND NON-RAPID EYE MOVEMENT (NREM) PARASOMNIAS

Sleep and migraine share a common pathophysiological substrate. While the mechanisms by which sleep deprivation or sleep dysfunction leads to headache are unknown, their association has been recognized for decades. The frontal aching headaches can develop both in normal subjects and in those who suffer from tension-type headaches who are deprived of sleep (1, 2).

The serotonergic system, well known as being central in the migraine attacks, demonstrates circadian and circannual rhythmicity. It is under control of the central nervous system (CNS), like other biorhythms (e.g., blood pressure). During the onset of a migraine attack, the urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA)—the main metabolite of serotonin—increases while platelet 5-hydroxytryptamine (5-HT) rapidly decreases. 5-HT pharmacologic depletion can induce a migraine attack and intravenous 5-HT can stop acute migraine attacks as well. Alike, during REM sleep when the dorsal raphe (DR) nucleus is silent, the systemic serotonin decreases. In part, this could explain the relationship between REM sleep and migraine. In addition, their relationship is also explained by the relationship between the hypothalamus (with other crucial regions involved in sleep regulation) and the areas engaged in nociception and migraine pathogenesis. These findings suggest that dysfunction in the sleep-regulating systems could generate headaches. Sleep loss may worsen pain, but not sleep fragmentation. As previously described in healthy mice, sleep loss increases the sensitivity to noxious stimuli without sensory hyperresponsiveness (3, 4). Moreover, the role of melatonin MT2 receptors in the antinociception modulation through the glutamatergic pathway (5) could also be considered and that melatonin levels are lower in the migraine sufferers regardless of the age, so suggesting its potential role as preventive therapy both for nociception modulation and sleep cycle regulation (6–12).

Headache and sleep have some anatomical and functional in common. The incidence of somnambulism (sleepwalking) may be increased in children with migraine (13, 14), and it has been proposed as a minor diagnostic criterion for migraine. On the other hand, serotonergic neurotransmission is involved during slow wave sleep (SWS), playing a predominant role in the migraine mechanisms. Clinical similarities such as genetic predisposition or reactivity to external stimuli suggest that migraine and somnambulism could have similar predisposing factors and perhaps common physiologic pathways. Medications used to treat migraine, such as propranolol (15) or amitriptyline (16), have sometimes induced, but most often cured, sleepwalking or other NREM parasomnias (17–19). In this hypothesis paper, we do not suggest that migraine headache and somnambulism may be part of the same pathology, but that migraine and somnambulism may follow a common pathway, either chemical or topographic (20, 21).

Several reports have described the association between migraine and NREM parasomnias in the pediatric age. Barabas et al. (13) performed the first study describing a correlation between these two disorders. Analyzing 4 groups of patients (60 with migraine, 42 with non-migraine headache, 60 with epilepsy, and 60 with learning disabilities/neurologic impairment), they found at least 2 episodes of somnambulism in 30% of migraineurs vs. 4.8% of those with non-migraine headaches, 5% of those with learning disabilities/neurologic impairment, and 6.6% of epileptics. Other studies confirmed these data. Pradalier et al. (15) found an incidence of sleepwalking in 21.9% of migraine subjects vs. 6.6% of controls. Giroud et al. (14) found a history of somnambulism in 29.4% of migraine subjects vs. 5.4% of non-migraine headache subjects. The analysis of different types of migraine showed that the highest prevalence was found in the ophthalmic migraine (70%), in common migraine (24%), and in classic migraine (20%). Noticing that the somnambulism appeared before migraine, those authors hypothesized that this sleep disorder and migraine could be a different age-related expression of the same neurotransmitter imbalance, probably of the serotonergic axis. The actual classification of headache disorders ICHD-3 (22) includes sleepwalking, sleep talking, night terrors, and bruxism among the additional conditions that may also occur in patients affected by migraine independently on sex and age (code 1.6). This suggests a close relationship between sleep disorders and migraine, particularly with disorders of arousal/NREM parasomnias (2, 23–30). In a study published in 1986 (31), Dexter asked to the parents of 100 migraineous patients about the occurrence of these disturbances (such as night terrors, sleepwalking, and nocturnal enuresis in the first 2 decades of life). Dexter found an incidence of 71% for night terrors/pavor nocturnus (vs. 11% of controls), 55% of somnambulism (vs. 16%
of controls), and 41% of nocturnal enuresis (vs. 16% of controls). These findings were similar to those described by Giroud in 1986 (14) and by Miller in 2003 (32), while another study failed to confirm these findings data (33).

Sleepwalking has been associated with migraine. Somnambulism and migraine can appear at different ages, the former during late infancy, the latter during childhood, and both could be linked to a different age-related expression of a serotonergic metabolic dysfunction (27), which could occur independently on sleep-disordered breathing. Instead, when both conditions are present, the association may be linked to the hypercapnic acidosis, which leads to a stimulation of serotonergic neurons, resulting in an increased excitability of motoneurons directing to the somnambulism (27, 34).

The relationship between sleep disturbance and migraine/headache could involve another fundamental neurobiological system, the orexin/hypocretin system, which seems to play a key role in regulating both the sleep/wake cycle and REM sleep (35), and it may also be associated with migraine pathogenesis. Indeed, orexin/hypocretin A and orexin/hypocretin B are hypothalamic excitatory neuropeptides that, in addition to regulating sleep/wake rhythm, play a role in many biological pathways involved in thermoregulation, energy metabolism control, mood and emotional regulation, energy homeostasis, reward mechanisms, drug cardiovascular responses, sexual behavior, nutritional behavior, and spontaneous physical activity (36–38). It is interesting to note that some symptoms associated with migraine such as tiredness, yawning, drowsiness, and desire for certain foods may be due to an involvement of the orexin/hypocretin system. In mammals, orexin/hypocretin A and orexin/hypocretin B are both synthesized from pre–pro-orexin in hypothalamic and central areas (39, 40). The orexin/hypocretin peptides influence two specific receptors: orexin/hypocretin 1-receptor (OX1R), localized in prefrontal cortex and infralimbic, hippocampus, amygdala, stria terminalis bed nucleus, paraventricular thalamus, front hypothalamus, median raphe (MR) nucleus, ventral tegmental area/pedunculopontine nucleus (41, 42), and orexin/hypocretin 2-receptor (OX2R), localized at amygdala, dorsal raphe (MR) nucleus, ventral tegmental nucleus, locus coeruleus and laterodorsal tegmental nucleus, lateral hypothalamus, stria terminalis bed nucleus, paraventricular thalamus, DR, ventral tegmental area/pedunculopontine nucleus, hippocampus, and median septal nucleus (42). The activity of orexin/hypocretin neurons is modulated by several neurotransmitters: GABA (43), noradrenaline, and serotonin inhibit the activity of orexin/hypocretin neurons (44); glutamate (45), cholecystokinin, neurotensin, oxytocin, and vasopressin seem to have instead an excitatory action on orexin neurons (46–48). The complex mechanisms by which the orexin/hypocretin system interacts with other brain systems and with the whole organism and the roles that these interactions may play are still to be clarified.

HYPOTHESIS/ THEORY

Neural pathways controlling sleep and pain are anatomically, physiologically, and neurochemically crossed. These neural systems are found in the brain, hypothalamus, and basal brain. The activity of the serotonergic nuclei of the cerebral trunk (MR nuclei) is physiologically reduced during REM sleep, and these structures are involved in anti-nociceptive control. About the main serotonergic system, the MR and DR nuclei provide parallel and overlapping projections to many forebrain structures with axon fibers exhibiting distinct structural and functional characteristics. Serotonin neurons within the MR nuclei show different interconnected with brain areas associated with emotion and motivation such as the amygdala, accumbens, and ventral pallidum nuclei. In contrast, the serotonin neurons in the MR are characterized by their domination over the septum and hippocampus (49). Serotonin pathways have been found to be important in the migraine pathophysiology. One of the main sleep–wake rhythm control systems is the orexin/hypocretin system (50). Orexin/hypocretin neurons are localized in the lateral hypothalamus and give projections throughout the brain and spinal cord, densely innervating the DR nucleus and MR nucleus, which contain serotonergic neurons (51).

Our hypothesis is that in migraines a dysfunction of orexinergic projections on the MR nuclei, interfering with serotonergic regulation, may cause NREM parasomnias, such as somnambulism.

EVALUATION OF THE HYPOTHESIS

Serotonin and orexin/hypocretin systems are anatomically and functionally interconnected. Serotonergic neurons receive excitatory input from hypothalamic orexin/hypocretin neurons and reciprocally inhibit orexin/hypocretin neurons through the 5HT1A receptor. It is possible that if this complex system is altered, it may facilitate the pathophysiological mechanisms involved in the migraine and on the other hand produce an alteration of the sleep–wake rhythm causing sleep disorders, such as sleepwalking. About the orexinergic innervation role in the migraine pathophysiology, axons immunoreactive to orexin/hypocretin A are reported as present at low density in lateral posterior (LP), and lateral dorsal (LD) nuclei of thalamus, and most median part of thalamic posterior complex (Po), and at very low density in ventral posterior median nucleus of thalamus (VPM) and most lateral part of Po (52). Moreover, if examined in sections containing the trigeminovascular neuron(s), low density of orexinergic immunopositive axons and varicosities appears to be close apposition to the proximal and distal dendrites but not the cell body (52, 53). These data show that the orexinergic axons originate mainly in the perifornical hypothalamic area. The orexin/hypocretin system originates in the LH and projects to the cortex, thalamus, brainstem, spinal cord, and other hypothalamic nuclei (39, 54–56). The wide distribution of orexin fibers in the brain supports a role in regulating food intake, arousal, wakefulness, and sympathetically mediated increase in body temperature, heart rate, sexual behavior, and blood pressure (57).

About the potential relevance for the pathophysiology of migraine, the orexinergic axons are in nociceptive laminae of the medullary dorsal horn and in close apposition to thalamic trigeminovascular neurons, although no data are yet available regarding the direction in which orexin/hypocretin may modulate the thalamic trigeminovascular neurons. In the migraine...
context, it is reasonable to hypothesize that the mechanism by which eating may reduce headache intensity involves not only local release of GABA from activated melanin-concentrating hormone (MCH)-expressing neurons but also inhibition of facilitatory orexin input to thalamic trigeminovascular neurons. These activities are induced by glucose level increase, considering that orexin/hypocretin neurons are inhibited by glucose (51, 58). The chemical pathway to modulate the activity of thalamic trigeminovascular neurons has been reported to be controlled mainly by glutamate, GABA, dopamine, and serotonin and in a minor level by noradrenaline and histamine, MCH, and orexin/hypocretin (52, 59).

Serotonin function has been long implicated in the pathophysiology of migraine (60, 61). However, the underlying mechanisms of this correlation are not fully clarified yet. It has been hypothesized (62) that a massive release of serotonin from the MR nucleus would be implicated in the activation of serotonergic receptors located on the walls of large cerebral vessels. This event could lead to abnormal vasodilatation increasing transmural pressure. Subsequently, the terminal trigeminal nerve is activated with consequent antidromal stimulation of sensory nerve endings at the level of hard vessels in the meninges, generating the release of pro-inflammatory peptides (substance P and CGRP). Within this hypothetical scheme, serotonin released may also interact with trigeminovascular afferents to activate and/or facilitate the release of the neuropeptide at the level of the trigeminal ganglion. In light of the mutual regulation of these two systems, serotonergic and orexigenic, it is plausible that at the basis of this serotonergic pathway dysfunction, there may be an alteration of the orexigenic system. This alteration, therefore, would cause the cascade of events leading to the onset of migraine pain and to the dysregulation of the sleep/wake cycle (Figure 1).

**DISCUSSION AND EMPIRICAL DATA**

Migraine is a chronic neurovascular disease characterized by recurrent headache associated with autonomic, gastrointestinal, and focal neurological symptoms, and it is often associated with mood disorders and sleep disturbances. Migraine is a public health problem with great impact on both patients and society. Prevalence is estimated to be about 30% for women and 25% for men (63). In addition, this disease also affects pediatric age, with a prevalence of 1–3% between 3 and 7 years, 4–11% between 7 and 11 years, and 8–28% of adolescents (13–18 years) (64). Migraine is classified as one of the most disabling chronic disorders of the World Health Organization. The annual cost of loss-related productivity associated with migraine is heavy and has been estimated as the most expensive neurological disorder in Europe (65). Although migraine is a neurological disorder that has been studied for many years, many aspects of its neurophysiopathology remain to be clarified. Among the neurobiological systems that could be implicated in the migraine etiopathogenesis, both serotonergic and orexigenic systems have been considered in numerous studies. These same systems could be involved in the onset of sleep disorders. Biochemical, genetic, and pharmacological studies have investigated potential dysfunction of serotonergic system in the migraine. For example, as previously described, 5-HT plasma levels are reduced in patients with migraine compared to controls, during attack-free periods (66, 67); in addition, the urinary excretion of 5-HIAA (the most important serotonin metabolite) decreases with the frequency of migraine attacks (68). Moreover, in the scientific literature, it is reported that platelets of migraineurs showing qualitative differences in their serotonin released reaction and clumping (69). Even neuroimaging studies (particularly PET studies) suggest that cerebral synthesis of serotonin can be quantitatively altered in migraineurs (70). The most commonly used drugs for treating migraine attacks are the triptans, selective agonists for serotonin 5-HT1B and 5-HT1D receptors. It was hypothesized that triptans could reduce migraine pain decreasing serotonin brain synthesis (71). In general, the very dense innervation of thalamic trigeminovascular neurons can provide an anatomical substrate for a predominantly inhibitory effect of serotonin on transmission of trigeminovascular information between the thalamus and the cortex, as well as the inhibition of trigeminovascular thalamic neurons by local administration of 5HT1 agonists (52, 72). The total absence of 5HT1D receptors in the thalamus region may suggest that inhibition of thalamic trigeminovascular neurons response to dural stimulation occurs at an earlier synapse along the trigeminovascular pathway (73).

Serotonergic neurons located in the MR nucleus are also involved in the regulation of the sleep/wakefulness cycle. As previously described, the destruction of these neurons or the administration of the inhibitor p-chloro-phenylalanine generates the insomnic habit that disappears restoring the synthesis of 5HT. The activity of serotonergic neurons in raphe dorsal nucleus is higher in wakefulness, lower during SWS, and almost quiescent during REM stages (74–77).

Specifically, orexins/hypocretins can regulate multiple homeostatic processes, including reward and arousal/wake state, exciting serotonergic DR and MR neurons (78, 79).

However, in which manner the serotonin regulates sleep/wake is still unclear. This neurotransmitter promotes waking and inhibits REM sleep in some cases, but it may also act as a sleep activator (80). These conflicting relationships could be due to the interaction between serotonergic neurons and other neurons involved in sleep/wake regulation, such as orexin/hypocretin neurons in the hypothalamus, which densely innervate serotonergic neurons in the MR nucleus, activating them directly and indirectly by binding OX1R and OX2R (81, 82).

In addition, orexin/hypocretin neurons receive dense serotonergic innervation and are inhibited by 5HT via the 5HT1A receptor, activating the GIRK channels (83, 84). It is not clear yet, though, how this circuit functions to regulate the sleep/wake cycle. It was described that orexigenic and serotonergic neurons located in raphe nuclei are more active in waking and less active during sleep SWS and REM. Moreover, as demonstrated in animal models, there is a critical role of the DRN–amygdale pathway in the orexigenic suppression of cataplectic episode (85). However, the level of activation of orexin/hypocretin cells is not directly related only to the arousal state, but they are less active during quiet wakefulness and discharge in active waking (86, 87). Regarding the role of orexin/hypocretin in the migraine, various studies suggest that mutation of the gene that encodes proteins involved in the orexin/hypocretin system may
play a role in the etiopathogenesis of migraine. In particular, it was described that the HCRTR1 gene (orexin/hypocretin receptor 1 gene) may be related to migraine (88) and that the 1246G/A polymorphism of the hypocretin receptor 2 (HCRTR2) gene is significantly associated with headache cluster (89). As already mentioned, the orexin/hypocretin system seems to play
REFERENCES

1. Blau N. Resolution of migraine attacks: sleep and the recovery phase. J Neurol Neurosurg Psychiatry (1982) 45(3):223–6. doi:10.1136/jnnp.45.3.223

2. Bellini B, Arruda M, Cescut A, Saule C, Persico A, Carotenuto M, et al. Headache and comorbidity in children and adolescents. J Headache Pain (2013) 14(1):79. doi:10.1186/1129-2377-14-79

3. Alexandre C, Latremoliere A, Ferreira A, Micara G, Yamamoto M, Scammell TE, et al. Decreased alertness due to sleep loss increases pain sensitivity in mice. Nat Med (2017) 23(6):768–74. doi:10.1038/nm.4329

4. Petit P, Altamura M, Iuso S, Padalino FA, Sessa F, D’Andrea G, et al. The relationship between personality traits, the SHTT polymorphisms, and the occurrence of anxiety and depressive symptoms in elite athletes. PLoS One (2016) 11(6):e0156601. doi:10.1371/journal.pone.0156601

5. Lopez-Canul M, Palazzo E, Dominguez-Lopez S, Luongo L, Lacoste B, Comai S, et al. Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways. Pain (2015) 156(2):305–17. doi:10.1097/01.pain.000046311.71572.5f

6. Lyon C, Langner S. PUR/Ls consider melatonin for migraine prevention. J Fam Pract (2017) 66(5):320–2.

7. Sangermani R, Boncimino A. The use of nutraceuticals in children’s and adolescent’s headache. Neurol Sci (2017) 38:121–4. doi:10.1007/s10072-017-2896-7

8. Toldo I, Rattin M, Perissinotto E, De Carlo D, Bolzonella B, Nosadini M, et al. Serotonin 5HTT polymorphisms and occurrence of anxiety and depressive symptoms in elite athletes. J Psychiatry (2017) 71(2):83–6. doi:10.1590/S0004-282X2017000500006

9. Toldo I, Rattin M, Perissinotto E, De Carlo D, Bolzonella B, Nosadini M, et al. Survey on treatments for primary headaches in 13 specialized juvenile Headache Centers: the first multicenter Italian study. Eur J Paediatr Neurol (2017) 21(3):507–21. doi:10.1016/j.ejpn.2016.12.009

10. Rosenberg K. Melatonin: safe and effective for the prevention of migraine headache. Am J Nurs (2016) 116(9):69. doi:10.1097/01.NAJ.0000494704.01488.c1

11. Gelfand AA, Goadsby PJ. The role of melatonin in the treatment of primary headache disorders. Headache (2016) 56(8):1257–66. doi:10.1111/head.12862

12. Masruha MR, de Souza Vieira DS, Minett TSC, Cipolla-Neto J, Zukerman E, Vilanova LCP, et al. Low urinary 6-sulphatoxyxalamin concentrations in acute migraine. J Headache Pain (2008) 9(4):221–4. doi:10.1007/s10194-008-0047-5

13. Masruha MR, Lin J, De Souza Vieira DS, Minett TSC, Cipolla-Neto J, Zukerman E, et al. Urinary 6-sulphatoxyxalamin levels are depressed in chronic migraine and several comorbidities. Headache (2010) 50(3):413–9. doi:10.1111/j.1526-4610.2009.01547.x

14. Giroud M, Atlan PD, Gourdeau O, Dumas R. Migraine et somnambulisme. Une enquête portant sur 122 migraineux. Rev Neurol (1986) 142:42–6.
31. Dexter JD. The relationship between disorders of arousal from sleep and migraine. *Headache* (1986) 26:322.

32. Miller JA, Pilgrim E, Tsa, Powen SW, Scher MS, Hershey AD. Migraine headaches and sleep disturbances in children. *Headache* (2003) 43(4):362–8. doi:10.1111/j.1526-4610.2003.03071.x

33. Luc ME, Gupta A, Birnberg JM, Reddick D, Kohrman MH. Characterization of symptoms of sleep disorders in children with headache. *Pediatr Neurol* (2006) 34(1):7–12. doi:10.1016/j.pediatrneurol.2005.06.009

34. Guelminault C, Palombini L, Pelayo R, Chervin RD. Sleepwalking and sleep terrors in prepuperal children: what triggers them? *Pediatrics* (2003) 111(1):e17–25. doi:10.1542/peds.111.1.e17

35. Kunnamgal BA, Kumar D, Mallick HC. Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep. *Behav Brain Res* (2013) 237(1):59–62. doi:10.1016/j.bbr.2012.09.015

36. Chieffi S, Carotenuto M, Monda V, Valenzano A, Villano I, Precenzano F, et al. Orexin system: the key for a healthy life. *Front Neural* (2017) 8:357. doi:10.3389/fnins.2017.00357

37. Francavilla G, Abbrignani MG, Braschi A, Sciaccia R, Francavilla VC, Caracciolo MM, et al. Physical exercise and sport activities in patients with and without coronary heart disease [Esercizio fisico ed attività sportiva in pazienti con e senza cardiopatia ischemica]. *Monaldi Arch Chest Dis Card Ser* (2007) 68(2):87–95. doi:10.4081/monaldi.2007.457

38. Gula KK, Mallick HC, Kumar VM. Orexin A (hypocretin-1) application at the medullary pre-Bötzinger complex activates male sexual behavior in rats. *Neuroscience* (2003) 116(4):921–3. doi:10.1016/S0366-6523(02)00877-3

39. Peyron C, Tighit DK, Van Den Pol AN, De Lecea L, Heller HC, Sutcliffe JG, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci* (1998) 18(23):9996–10015.

40. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Neurons expressing orexin neurites give rise to the raphespinal neurons. *Brain Res* (2003) 982:253–61.

41. Trivedi P, Yu H, MacNeil DJ, Van Der Ploeg LH, Guan X-M. Distribution of orexin neurons in the adult rat brain. *Brain Res* (1998) 816(1–2):109–12. doi:10.1016/S0006-8993(99)01336-0

42. Nambu T, Sakurai T, Doi S, Goto K. Distribution of orexin neurons in the adult rat brain. *Brain Res* (1999) 817(1–2):243–60. doi:10.1016/S0006-8993(99)01336-0

43. Terron JA. Is the 5-HT7 receptor involved in the pathogenesis and prophylactic treatment of migraine? *Eur J Pharmacol* (2002) 439(1–3):1–11. doi:10.1016/S0014-2999(02)01266-6

44. Gasparini CF, Smith RA, Griffiths LR. Genetic and biochemical changes of the NMDA receptor in migraine. *Brain Res* (2003) 972(1):83–92. doi:10.1016/S0006-8993(02)03078-6

45. Hsu JH, Supronsinchai W, Akerman S, Andreou AP, Winrow CJ, Renger J, et al. Evidence for orexinergic mechanisms in migraine. *Neurobiol Dis* (2015) 72:267–75. doi:10.1016/j.nbd.2015.01.017

46. Broberger C, De Lecea L, Sutcliffe JG, Hökfelt T. Hypocretin/orexin- and melatonin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide y and agouti gene-related protein systems. *J Comp Neurol* (1998) 409(4):442–59. doi:10.1002/1096-9861(19981228)402:4<460::AID-CNE3>3.0.CO;2-S

47. Girault EM, Yi C-X, Fliers E, Kalsbeck A. Orexins, feeding, and energy balance. *Prog Brain Res* (2012) 198:47–64. doi:10.1016/B978-0-444-59489-1.00005-7

48. Prabhakar CB, Lipton RB. Prevalence of frequent headache disorders in India: a population-based study. *Headache* (2009) 49(12):1768–78. doi:10.1111/j.1526-4610.2009.01132.x

49. Lipton RB, Buse DC, Bigal ME, Diamond MB, Goadsby PJ, et al. The American Migraine Prevalence and Prevention Study (AMPPS): baseline characteristics of study subjects. *Headache* (2006) 46(3):310–21. doi:10.1111/j.1526-4610.2006.00691.x

50. Messina et al. Orexinergic System Influences Sleep and Migraine. *Frontiers in Neurology* | www.frontiersin.org 7 February 2018 | Volume 9 | Article 95
Messina et al.

Orexinergic System Influences Sleep and Migraine

74. Adrien J. Neurobiological bases for the relation between sleep and depression. Sleep Med Rev (2002) 6(5):341–51. doi:10.1016/S1087-0792(01)90200-X

75. Jouvet M. Sleep and serotonin: an unfinished story. Neuropsychopharmacology (1999) 21:245–78. doi:10.1016/S0893-133X(99)00069-3

76. McGinty DJ, Harper RM. Dorsal raphe neurons: depression of firing during sleep in cats. Brain Res (1976) 101(3):569–75. doi:10.1016/0006-8993(76)90480-7

77. Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW. Control of sleep and wakefulness. Physiol Rev (2012) 92(3):1087–18. doi:10.1152/physrev.00032.2011

78. Ishibashi M, Gumenchuk I, Miyazaki K, Inoue T, Ross WN, Leonard CS. Hypocretin/orexin peptides after spike encoding by serotonergic dorsal raphe neurons through two distinct mechanisms that increase the late afterhyperpolarization. J Neurosci (2016) 36(39):10097–115. doi:10.1523/JNEUROSCI.0635-16.2016

79. Intusuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Front Endocrinol (2013) 4:18. doi:10.3389/fendo.2013.00018

80. Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev (2011) 15(4):269–81. doi:10.1016/j.smrv.2010.11.003

81. Liu R-J, Van Den Pol AN, Aghajanian GK. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci (2002) 22(11):9453–64.

82. Brown RE, Sergeeva OA, Eriksson KS, Haas HL. Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin, hypocretin, histamine and noradrenaline). J Neurosci (2002) 22(20):8850–9.

83. Sakurai T, Nagata R, Yamanaka A, Kawamura H, Tsujino N, Muraki Y, et al. Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. Neurog (2005) 46(2):297–308. doi:10.1101/j.neuron.2005.03.010

84. Muraki Y, Yamanaka A, Tsujino N, Khalid TS, Goto K, Sakurai T. Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. J Neurosci (2004) 24(32):7159–66. doi:10.1523/JNEUROSCI.1027-04.2004

85. Hasegawa E, Maejima T, Yoshida T, Massiek OA, Herlitze S, Yoshioke M, et al. Serotonin neurons in the dorsal raphe mediate the antinociceptive action of orexin neurons by reducing amygdala activity. Proc Natl Acad Sci U S A (2017) 114(17):E3526–35. doi:10.1073/pnas.1614552114

86. Mileykovskiy BY, Kyiashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron (2005) 46(5):787–98. doi:10.1016/j.neuron.2005.04.035

87. Cacopardo B, Pinzone MR, Berretta S, Fisichella R, Di Vita M, Zanghì G, et al. Hypocretin, histamine and noradrenaline). J Neurosci (2004) 21(23):8614–9. doi:10.1523/JNEUROSCI.0635-16.2016

88. Rainero I, Rubino E, Gallone S, Fenoglio P, Picci LR, Giobbe L, et al. Impact of a weight loss program on migraine in obese adolescents. Eur J Neurosci (2013) 20(2):394–7. doi:10.1111/j.1468-1727.2012.07371.x

89. Rainero I, Carotenuto M, Altieri L, Parisi P, Tozzi E, Belcastro V, et al. Migraine and obesity: metabolic parameters and response to a weight loss programme. Pediatr Obes (2015) 10(3):220–5. doi:10.1111/jo.245

90. Verrotti A, Di Fonzo A, Pentà L, Agostoni S, Parisi P. Obesity and headache/migraine: the importance of weight reduction through lifestyle modifications. Biomed Res Int (2014) 2014:420858. doi:10.1155/2014/420858

91. Verrotti A, Di Fonzo A, Agostoni S, Coppola G, Margiotta M, Parisi P. Obese children suffer more often from migraine. Acta Paediatr (2012) 101(9):e416–21. doi:10.1111/j.1651-2227.2012.02768.x

92. Verrotti A, Agostoni S, D’Egidio C, Di Fonzo A, Carotenuto M, Parisi P, et al. The link between obesity and migraine in children: a systematic review. Ital J Pediatr (2017) 43(1):27. doi:10.1186/s13052-017-0344-1

93. Messina G, Viggiano A, Tafuri D, Palmieri F, De Blasio S, Messina A, et al. Role of orexin in obese patients in the intensive care unit. J Anesth Clin Res (2014) 5(3):100395. doi:10.4172/2155-6148.100395

94. Messina G, Monda V, Moscatelli F, Valenzano AA, Monda G, Esposito T, et al. Role of orexin system in obesity. Biol Med (2015) 7(4):1002248. doi:10.4172/0974-8369.1002248

95. Julliard A-K, Al Koborsy D, Fadool DA, Palouzier-Paulignan B. Nutrient sensing: another chemosensitivity of the olfactory system. Front Physiol (2017) 8:468. doi:10.3389/fphys.2017.00468

96. Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. Neurology (2006) 66(4):545–50. doi:10.1212/01.wnl.0000197218.05284.8d

97. Farello G, Ferrara P, Antenucci A, Basti C, Vernotti A. The link between obesity and migraine in childhood: a systematic review. Ital J Pediatr (2017) 43(1):27. doi:10.1186/s13052-017-0344-1

98. Viggiano A, Carotenuto M, Altieri L, Parisi P, Tozzi E, Belcastro V, et al. Migraine and obesity: metabolic parameters and response to a weight loss programme. Pediatr Obes (2015) 10(3):220–5. doi:10.1111/jo.245

99. Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, YANAGISAWA M, et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci (2001) 21(5):1566–62.

100. Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport (2001) 12(5):993–7. doi:10.1097/00001756-200104170-00026

101. Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, et al. Role of orexin system in obesity. J Neurosci (2015) 7(4):1002248. doi:10.4172/0974-8369.1002248

102. Dahmen N, Kasten M, Wiezorek S, Gencik M, Epplen JT, Ulbrick R. Increased frequency of migraine in narcoleptic patients: a confirmatory study. Cephalalgia (2003) 23(11):14–9. doi:10.1080/033107603000343.x

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Messina, Bitetti, Precenzano, Iacono, Messina, Roccella, Parisi, Salerno, Valenzano, Maltese, Salerno, Sessa, Albanò, Marrotta, Villano, Marsala, Zammit, Lavano, Monda, Cibelli, Lavano, Gallus, Toraldo, Monda and Carotenuto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.